EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Completed
Duke Clinical Research Institute
Phase 3
2004-11-01
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients
with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death,
heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed
provisional use of eptifibatide).
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2004-11-01
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients
with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death,
heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed
provisional use of eptifibatide).
Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial
Completed
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 1/Phase 2
2003-07-01
The purpose of this study is determine the effects of using of a combination of two
drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator,
rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
